Mean change in baseline CDAI (Random effects model) · patients with Induction of remission or response in Crohn's disease
1 finding from 1 review
Mean change in baseline CDAI (Fixed effects model) · patients with Induction of remission or response in Crohn's disease
1 finding from 1 review
Frequency of defecation (mean number of bowel movements per week) · patients aged 0 to 18 years with a diagnosis of functional constipation
1 finding from 1 review
Serious adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
PEG showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
QoL · patients with chronic pancreatitis and pancreatic pain
1 finding from 1 review
Serious adverse events · patients with chronic pancreatitis and pancreatic pain
Pregabalin showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Opiate analgesic requirement (short‐term) · patients with chronic pancreatitis and pancreatic pain
1 finding from 1 review
Adverse events · patients with chronic pancreatitis and pancreatic pain
Pregabalin probably leads to higher adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Pain scores (short‐term) · patients with chronic pancreatitis and pancreatic pain
1 finding from 1 review
Hospital admissions · patients with chronic pancreatitis and pancreatic pain
Pregabalin showed no clear difference in hospital admissions compared with placebo (low certainty).
1 finding from 1 review
Maintenance of remission · maintenance of remission in Crohn's disease
Azathioprine or 6‐mercaptopurine may leads to higher maintenance of remission (sensitivity analysis excluding Candy 1995) compared with placebo (low certainty).
1 finding from 1 review
Adverse events · maintenance of remission in Crohn's disease
Azathioprine or 6‐mercaptopurine may leads to higher adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Budesonide 3 mg showed no clear difference in induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Budesonide 15 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Clinical improvement (decrease in CDAI > 100 or total CDAI <= 150) ‐ 8 weeks · Patients with active Crohn's disease
Budesonide 15 mg showed no clear difference in clinical improvement (decrease in CDAI > 100 or total CDAI <= 150) ‐… compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 15 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawal due to disease worsening · Patients with active Crohn's disease
Budesonide 15 mg probably leads to lower withdrawal due to disease worsening compared with placebo (moderate certainty).
1 finding from 1 review
Corticosteroid related adverse events · Patients with active Crohn's disease
Budesonide 15 mg showed no clear difference in corticosteroid related adverse events compared with placebo (moderate certainty).
1 finding from 1 review